Heidi Ko/LinkedIn
Dec 14, 2024, 16:11
Heidi Ko: Presentation of results from ZEST trial on the reality of MRD use in early breast cancer
Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, shared a post on LinkedIn:
“What a wonderful discussion by Dr. Krop and presentation of results from ZEST trial by Dr. Turner on the reality of MRD use in early breast cancer.
We are not there yet to use MRD testing as SOC in breast cancer, unlike in colon cancer where we now have evidence for ctDNA-guided therapy.
A few key points that they have highlighted as we think about future prospective trials.
- Identifying the relatively high-risk patients
- Testing the patients as early as possible from completion of standard therapy (because patients with TNBC have early recurrences)
- Improving the sensitivity of ctDNA testing
- Proving clinical utility of a test matters because testing can be associated with potential harms (increased toxicity from early intervention, potentially discontinuing an effective therapy, anxiety and false reassurance).”
More posts featuring Heidi Ko.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 14, 2024, 15:57
Dec 14, 2024, 15:53
Dec 14, 2024, 15:44
Dec 14, 2024, 15:32
Dec 14, 2024, 13:54